Scientific Publications

To request copies of papers or articles, please send an email with your request to

Abstracts

Barclay, L., Anderson, R. and Morley, P. Ostabolin-C™: A Phase I trial to assess its safety, tolerability and pharmacokinetics in healthy older women. International Osteoporosis Foundation (IOF) World Congress on Osteoporosis, Toronto, June 2-6, 2006.

Morley, P., Jolette, J., Smith, S.Y., Turner, C.H., Moreau, I., Mayer, J. Ostabolin-C™: A novel parathyroid hormone analogue increases bone formation and strength in rats treated for 26 weeks. International Osteoporosis Foundation (IOF) World Congress on Osteoporosis, Toronto, June 2-6, 2006.

Barclay, L., Anderson, R. and Morley, P. Ostabolin-C™: A Phase I trial to assess its safety, tolerability and pharmacokinetics in healthy older women. 6th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Vienna, Austria, March 15-18, 2006.

Jolette, J., Smith, S.Y., Moreau, I., Turner, C.H., Mayer, J., Rushton, B., Morley, P. Ostabolin-C™: A novel parathyroid hormone analogue uncouples bone turnover in monkeys treated for 1-year. American Society of Bone and Mineral Research, Nashville, TN, September 23-25, 2005.

To see an archived list of older abstracts, click here.

Research Papers

Morley, P. Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opinion on Drug Delivery 2:993-1002, 2005.

Thompson, C., Morley, P., Kirkland, D and Proudlock, R. Modified bacterial mutation test procedures for evaluation of peptides and amino acid-containing material. Mutagenesis 20:345-350, 2005.

Willick, G.E., Morley, P. and Whitfield, J.F. Constrained analogues of osteogenic peptides. Current Medicinal Chemistry 11:2599-2613, 2004.

Gittens, S.A., Wohl, G.R., Zernicke, R.F., Matyas, J.R., Morley, P. and Uludag, H. Systemic bone formation with weekly PTH administration in ovariectomized rats. Journal of Pharmacy and Pharmaceutical Sciences 7:27-37, 2004.

Andreassen, T.T., Willick, G.E., Morley, P. and Whitfield, J.F. Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31) and monocyclic hPTH(1-31) enhances fracture strength and callus amount – After withdrawal fracture strength and callus mechanical quality continue to increase. Calcified Tissue International 74:351-356, 2004.

To see a list of archived research papers, click here.